Misplaced Pages

ApiJect Systems

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
ApiJect Systems
[REDACTED]
IndustryMedical technology
Founded2018; 7 years ago (2018)
FounderMarc Koska
HeadquartersStamford, Connecticut
Key people
ProductsPre-filled Injectors
Websiteapiject.com

ApiJect Systems Corporation is an American company founded in 2018 by Marc Koska and based in Stamford, Connecticut that produces pre-filled single use plastic injectors. ApiJect works with pharmaceutical and biotech companies to fill their injectable drug products into single-dose prefilled injectors. The company claimed to have the capacity to manufacture pre-filled COVID-19 vaccine syringes by the end of 2020.

History

ApiJect Systems was founded in 2018 by Marc Koska, who invented the ApiJect injector, a prefilled, single-use plastic injector, as a low cost way to get medicine to poorer countries. Koska previously invented the self-locking K1 syringe to prevent needle reuse.

In 2020, ApiJect pivoted in order to meet U.S. demand for COVID-19 vaccinations. In May 2020, the U.S. Department of Health and Human Services and the U.S. Department of Defense signed a $138 million deal with ApiJect, called Project Jumpstart, to facilitate the production of 100 million prefilled syringes by the end of 2020 and 500 million in 2021 in the event that a COVID-19 vaccine became available.

In November 2020, ApiJect was approved for a $590 million loan from the U.S. International Development Finance Corporation to construct a multi-facility campus. The project broke ground in February 2021 in Durham, North Carolina, and was among the largest projects in the nation to break ground that month. The factory is designed to deliver production capacity of up to 2 to 3 billion units annually. It will be suitable for vaccines requiring standard cold storage, including those in need of ultra-cold storage down to -70 degrees Celsius.

As of April 21, 2021 the company has failed to produce any syringes, however it has met its obligations under its federal contracts and loan commitments by lining up a subcontractor that promises to produce the syringes once they obtain FDA approval. The CEO of the company stated in July 2020: "The fact of this matter is, it would be crazy for people to just rely on us...We should be America’s backup at this point, but probably not its primary.” According to the White House 100 Days report of June 2021, Health and Human Services is planning to expand Project Jumpstart to $250 million per month through 2023.

In December 2021, ApiJect and Fareva announced a licensing agreement to establish three Blow-Fill-Seal manufacturing lines in France.

In April 2022, ApiJect opened the ApiJect Technology Development Center in Florida, with research and development investment from the U.S. Office of the Assistant Secretary for Preparedness and Response and the U.S. Department of Defense. The center works with pharmaceutical companies to develop prefilled injectors.

In May 2022, ApiJect raised $111 million from Royalty Pharmaceuticals and Jefferies Financial Group, valuing ApiJect at approximately $300 million.

Product

ApiJect’s prefilled injector uses Blow-Fill-Seal (BFS) manufacturing technology, which is recognized as an advanced aseptic liquid packaging process.  The prefilled injector is created by screwing the pen needle-style hub onto the top of the BFS container. BFS process uses pharmaceutical-grade plastic resin to create, fill and seal a strip of 12-to-25 drug containers per production line every three seconds.

References

  1. "ApiJect picks up $111M investment from Royalty Pharma, Jefferies" (website). drugdeliverybusiness.com.
  2. "ApiJect Systems Corp - Company Profile and News". Bloomberg.com. Retrieved 2021-04-21.
  3. "ApiJect Systems, Corp., Announces Appointment of Global Branding Leader, Craig Cohon as Chief Strategy Officer". www.prnewswire.com. Retrieved 2021-04-21.
  4. ^ "Stamford company may play critical role in COVID vaccine delivery". fox61.com. Retrieved 2021-06-29.
  5. "Special Feature – PFS & Parenteral Drug Delivery: Self-Injection is Very Much the "New Normal"". Drug Development and Delivery. 2022-05-02. Retrieved 2022-06-27.
  6. "ASPR celebrates construction of new research and development facility for production of prefilled injectors". Homeland Preparedness News. 2022-04-25. Retrieved 2022-06-27.
  7. How Soft Plastic Vials Can Help Fight the Coronavirus Outbreak, retrieved 2021-04-22
  8. ApiJect CEO Expects Therapy to Blunt Coronavirus Death Rate by Summer, retrieved 2021-04-22
  9. "Trump admin to ramp up syringe production for future COVID-19 vaccine". NBC News. Retrieved 2021-04-21.
  10. ^ "U.S. Bets On Small, Untested Company to Deliver COVID Vaccine". Frontline. Retrieved 2021-09-01.
  11. "4 innovations that found their use case during the pandemic - News". MM+M - Medical Marketing and Media. 2021-03-09. Retrieved 2021-06-29.
  12. "Trump admin to ramp up syringe production for future COVID-19 vaccine". NBC News. Retrieved 2021-06-29.
  13. ^ "ApiJect snares $590M government loan for 'Gigafactory' to produce billions of prefilled vaccine injectors per year". FiercePharma. Retrieved 2021-06-29.
  14. Buckshon, Mark. "$785 million ApiJect Gigafactory in Durham among largest projects in nation to start, despite overall national decline: Dodge". Retrieved 2021-06-29.
  15. ^ "Special Feature – PFS & Parenteral Manufacturing: How COVID-19 Changed the Market". Drug Development and Delivery. 2021-05-03. Retrieved 2021-06-29.
  16. "The U.S. awarded a firm $1.3 billion to make syringes. Where are they?". NBC News. Retrieved 2021-04-21.
  17. "The U.S. awarded a firm up to $1.3 billion to make syringes. Where are they?". NBC News. Retrieved 2021-06-29.
  18. "U.S. Bets On Small, Untested Company to Deliver COVID Vaccine". Frontlin. Retrieved 2021-04-21.
  19. "Building Resilient Supply Chains, Revitalizing American Manufacturing, and Fostering Broad-Based Growth" (PDF). WhiteHouse.gov. Archived (PDF) from the original on 2021-06-08.
  20. Whooley, Sean (2021-12-09). "Fareva, ApiJect ink 10-year licensing agreement on fill-finish production lines". Medical Design and Outsourcing. Retrieved 2022-08-05.
  21. Staff Reports (2022-04-13). "ApiJect Systems opens technology development center in Orlando". Florida Politics. Retrieved 2022-08-05.
  22. Galford, Chris (2022-04-25). "ASPR celebrates construction of new research and development facility for production of prefilled injectors". Homeland Preparedness News. Retrieved 2022-08-05.
  23. Keenan, Joseph (2022-05-19). "Syringe maker ApiJect reels in $111M in private investment round". Fierce Pharma. Retrieved 2022-08-05.
  24. Whooley, Sean (2022-05-18). "ApiJect picks up $111M investment from Royalty Pharma, Jefferies". Drug Delivery Business. Retrieved 2022-08-05.
  25. ^ "ApiJect selects IPS for Greenfield blow-fill-seal aseptic manufacturing campus". cleanroomtechnology.com. Retrieved 2021-06-29.

External links

COVID-19 pandemic
Timeline
Pre-pandemic
2020
2021
2022
2023
Locations
Africa
Northern
Eastern
Southern
Central
Western
Asia
Central/North
East
Mainland China
South
India
By location
Southeast
Malaysia
Philippines
West
Europe
United Kingdom
By location
Eastern
Western Balkans
European Union
EFTA countries
Microstates
North
America
Atlantic
Canada
Caribbean
Countries
British Overseas Territories
Caribbean Netherlands
French West Indies
US insular areas
Central America
United States
responses
By location
Oceania
Australia
New Zealand
South
America
Others
Impact
Culture and
entertainment
Arts and
cultural heritage
Education
By country
Sports
By country
By sport
Society
and rights
Social impact
Labor
Human rights
Legal
Minority
Religion
Economic
By country
By industry
Supply and trade
Financial markets
Information
Misinformation
Politics
Political impact
Protests
International relations
Language
Others
Health issues
Medical topics
Testing and
epidemiology
Apps
Prevention
Vaccines
Topics
Authorized
DNA
Inactivated
mRNA
Subunit
Viral vector
Virus-like particles
In trials
Attenuated
DNA
Inactivated
RNA
Subunit
Viral vector
Virus-like particles
Deployment
by location
Africa
Asia
Europe
North America
Oceania
South America
Others
Treatment
Monoclonal antibodies
Small molecule antivirals
Variants
Specific
General
Institutions
Hospitals and
medical clinics
Mainland China
Others
Organizations
Health
institutes
Pandemic
institutes
Relief funds
People
Medical
professionals
Researchers
Officials
WHO
By location
Others
List of deaths due to COVID-19
Data (templates)
Global
Africa
Americas
Asia
Europe
Oceania
Others
Categories:
ApiJect Systems Add topic